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Abstract
The	 landscape	of	genetic	alterations	 in	disease	models	 such	as	 transgenic	mice	or	
mice	with	carcinogen-induced	 tumors	has	provided	a	huge	amount	of	 information	
that	has	shed	light	on	the	process	of	tumorigenesis	in	human	non-small-cell	lung	can-
cer	(NSCLC).	We	have	previously	identified	stratifin	(SFN)	as	a	potent	oncogene,	and	
generated	SFN-transgenic	 (Tg-SPC-SFN+/−)	mice,	which	express	human	SFN	(hSFN)	
only	 in	 the	 lung.	Here,	we	have	 found	 that	carcinogen	nicotine-derived	nitrosami-
noketone	 (NNK)-induced	 tumors	developing	 in	Tg-SPC-SFN+/− mice show a similar 
histology	to	human	lung	adenocarcinoma	and	exhibit	high	hSFN	expression.	In	order	
to	compare	the	genetic	characteristics	of	Tg-SPC-SFN+/−	tumors	and	human	lung	ad-
enocarcinoma,	the	former	were	subjected	to	whole-exome	sequencing.	Interestingly,	
Tg-SPC-SFN+/−	 tumors	 showed	 the	 distinct	 distribution	 of	 exonic	 mutations	 and	
high	number	of	mutated	genes	and	transversion.	Moreover,	Tg-SPC-SFN+/−	tumors	
showed	73	genes	that	were	commonly	detected	in	more	than	2	tumors,	mutations	
of	which	were	also	found	in	human	lung	adenocarcinoma.	The	expression	levels	of	
some	of	these	genes	were	significantly	associated	with	the	clinical	outcome	of	lung	
adenocarcinoma	 patients.	 Additionally,	 mutated	 genes	 in	 Tg-SPC-SFN+/−	 tumors	
were	 closely	 associated	with	 key	 canonical	 pathways	 such	 as	 PI3K/AKT	 signaling	
and	apoptosis	signaling.	These	results	suggest	that	SFN	overexpression	is	a	universal	
abnormality	in	human	lung	adenocarcinogenesis	and	Tg-SPC-SFN+/−	tumors	recapit-
ulate	key	features	of	major	human	lung	adenocarcinoma.	Therefore,	Tg-SPC-SFN+/− 
mice	provide	a	useful	model	for	clarifying	the	molecular	mechanism	underlying	lung	
adenocarcinogenesis.
K E Y W O R D S
lung	adenocarcinoma,	mutational	signature,	nicotine-derived	nitrosaminoketone,	stratifin,	
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1  | INTRODUC TION
Lung	cancer	is	the	most	frequent	cause	of	cancer-related	mortality	
worldwide1,2	due	to	its	unsatisfactory	cure	rate	and	poor	progno-
sis,	and	is	divided	into	2	major	histological	subtypes:	small-cell	lung	
cancer	 and	 non-small-cell	 lung	 cancer	 (NSCLC).3	 Lung	 adenocar-
cinoma,	 the	 predominant	 type	 of	NSCLC,	 is	 considered	 to	 show	
a	multistep	process	of	carcinogenesis.	Atypical	adenomatous	hy-
perplasia	progresses	to	adenocarcinoma	in	situ,	and	subsequently	
to	 invasive	 adenocarcinoma	 with	 specific	 molecular	 alterations	
that	 are	 responsible	 for	 both	 the	 initiation	 and	 maintenance	 of	
tumorigenesis.4
Previously,	we	 examined	 the	 gene	 expression	 profiles	 of	 early	
stage	 lung	 adenocarcinomas5	 and	 identified	 stratifin	 (SFN,	 14-3-3	
sigma),	which	showed	significantly	higher	expression	in	small	but	in-
vasive	lung	adenocarcinoma	(tumor	size	less	than	3	cm	in	diameter)	
than	in	adenocarcinoma	in	situ	or	normal	lung.5,6	Overexpression	of	
SFN	 is	due	 to	DNA	hypomethylation	 in	 its	promoter	 region7,8 and 
is	 associated	with	poor	patient	outcome	 in	 lung	adenocarcinoma.9 
We	have	 found	 that	 suppression	of	SFN	 reduces	 cell	 proliferation	
in	vitro9,10	and	tumor	formation	or	metastasis	 in	vivo,11	suggesting	
that	SFN	facilitates	tumor	progression.	Consistently,	SFN-transgenic	
mice	(Tg-SPC-SFN+/−),	which	express	human	SFN	(hSFN)	only	in	the	
lung	under	control	of	the	SPC	promoter,	a	lung-specific	enhancer,	de-
velop	lung	tumors	spontaneously,11	implying	that	SFN	has	oncogenic	
potential	 in	 the	context	of	 lung	adenocarcinogenesis.	Additionally,	
overexpression	of	SFN	dysregulates	signal	transduction	associated	
with	cellular	proliferation,	the	cell	cycle,	apoptosis,	and	protein	traf-
ficking	by	interacting	with	phosphorylated	serine	or	threonine	in	the	
binding	partner	proteins.9,10,12
Genetic	 imbalances	of	DNA	or	mRNA	sequences	 in	the	cancer	
genome	trigger	various	genetic	alterations	during	the	process	of	tu-
morigenesis.	Unlike	the	situation	in	early	stage	lung	adenocarcinoma,	
many	 studies	 have	 revealed	 comprehensive	 somatic	 mutations	 in	
advanced	 lung	 adenocarcinomas	 using	 whole-exome	 sequencing	
(WES),13	which	has	high	accuracy,	 high	 sensitivity,	 and	 cost	 effec-
tiveness	for	identifying	driver	mutations14,15	and	can	predict	the	ef-
ficacy	of	 anticancer	 agents	 such	 as	molecular	 targeting	drugs	 and	
immune	checkpoint	 inhibitors.16	Transgenic	mice	or	mice	with	car-
cinogen-induced	tumors	can	be	used	to	assess	potential	molecular	
alterations	related	to	human	tumorigenesis.	Transgenic	mouse	mod-
els	 of	 oncogenetic	 activation	 show	 frequent	 aneuploidy	 and	 copy	
number	 alteration,	 but	 few	 somatic	 single-nucleotide	 variants.17 
However,	carcinogens	such	as	methyl-nitrosourea	and	nicotine-de-
rived	nitrosaminoketone	 (NNK)	 included	 in	 tobacco	 smoke	 initiate	
tumorigenesis	through	induction	of	numerous	deleterious	mutations	
at	the	loci	of	oncogenes	such	as	KRAS17,18	or	tumor	suppressor	genes	
such as TP53.19,20	In	this	regard,	we	have	been	able	to	recapitulate	
the	early	stage	of	human	lung	adenocarcinoma	using	Tg-SPC-SFN+/− 
mice	 treated	with	NNK	to	 trigger	 tumorigenesis.	This	has	clarified	
the	genetic	profile	of	lung	tumors	developing	in	Tg-SPC-SFN+/−	mice,	
thus	helping	to	identify	the	gene	alterations	contributing	to	human	
lung	adenocarcinogenesis.
In	 the	 present	 study,	 we	 investigated	 the	 genetic	 landscape	
of	NNK-induced	 lung	adenocarcinomas	 in	a	Tg-SPC-SFN+/−	back-
ground.	 Paired	 samples	 of	 tumor	 tissue	 and	 normal	 lung	 were	
subjected	to	WES,	and	mutated	genes	associated	with	SFN	over-
expression	 in	 lung	 adenocarcinoma	 were	 examined.	 Here,	 we	
emphasize	the	importance	of	SFN	overexpression	in	lung	adeno-
carcinogenesis	and	show	that	Tg-SPC-SFN+/− mice provide a valu-
able	model	 for	 clarifying	early	genetic	alterations	 in	human	 lung	
adenocarcinoma.
2  | MATERIAL S AND METHODS
2.1 | SFN transgenic mouse model and pathological 
analysis
We	generated	the	Tg-SPC-SFN+/−	strain	from	ICR	mice	that	had	been	
purchased	from	(Charles	River	Laboratories,	Tsukuba,	Japan),	as	de-
scribed previously.11	Wild-type	(WT)	and	Tg-SPC-SFN+/− mice were 
given	a	single	i.p.	dose	of	4	mg	NNK	(Toronto	Research	Chemicals,	
North	York,	ON,	Canada)	 dissolved	 in	 saline	 to	 induce	 pulmonary	
tumors.	Twenty	weeks	 after	NNK	 treatment,	 all	 of	 the	mice	were	
killed,	 and	 the	 induced	 tumors	were	 resected	 from	 the	 lungs.	The	
resected	 tumors	were	partially	 fixed	with	 formalin	 for	histological	
analysis	 including	 hematoxylin	 and	 eosin	 (H&E)	 staining	 and	 im-
munohistochemistry	 for	 hSFN,	 as	 described	previously,11 and also 
frozen	in	liquid	nitrogen	for	WES	and	stored	at	−80°C	until	DNA	ex-
traction.	All	animal	experiments	were	approved	by	the	Institutional	
Animal	 Experiment	 Committee	 of	 the	 University	 of	 Tsukuba	
(Tsukuba,	Japan).
2.2 | Library preparation and WES
The	WES	 libraries	were	prepared	with	 the	NEBNext	DNA	Library	
Prep	Master	Mix	Set	(New	England	Biolabs,	Ipswich,	MA,	USA)	and	
a	SeqCap	EZ	Developer	Library	kit	(NimbleGen;	Roche,	Pleasanton,	
CA,	USA)	from	0.5	μg	of	genomic	DNA.	The	quality	of	the	DNA	library	
was	evaluated	using	Agilent	2100	Bioanalyzer	(Agilent	Technologies,	
Santa	Clara,	CA,	USA).	Sequencing	of	the	multiplexed	library	using	
a	NextSeq	500	sequencer	 (Illumina,	San	Diego,	CA,	USA)	was	car-
ried	out	and	the	data	were	imported	to	CLC	Genomics	Workbench	
software	(version	10.1.1;	Qiagen,	Hilden,	Germany).	Sequences	were	
mapped	 to	 the	 GRCm38/mm10	 mouse	 reference	 and	 annotated	
using	Ensemble,	Hanava,	or	Ensemble	and	Hanava	merged	transcript	
database.	(http://www.ensem	bl.org/index.html)	
Possible	 single-nucleotide	polymorphisms	or	 possible	 ICR	drift	
mutations	were	 excluded	 from	 the	data	 as	 follows:	 (a)	 single	base	
substitutions	 common	 to	 each	 normal	 lung	 sample	were	 removed	
from	datasets	of	tumor	samples,	(b)	single	base	substitutions	found	
in	normal	lung	samples	from	WT	or	Tg-SPC-SFN+/−	mice	treated	with	
saline	were	also	removed	from	each	dataset.	In	addition,	we	under-
took	filtering	based	on	the	following	criteria:	single	nucleotide	vari-
ant	type	with	nonsynonymous	mutation;	coverage	of	reads	10%	or	
higher;	frequency	10%	or	higher;	variant	at	least	5	bases	away	from	
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the	end	of	 the	read;	and	an	average	variant	quality	score	of	20	or	
more.
2.3 | Bioinformatics analysis
Mutations	were	first	categorized	 into	6	types	according	to	the	se-
quence	on	the	coding	strand	(C:G>A:T,	C:G>G:C,	C:G>T:A,	T:A>A:T,	
T:A>C:G,	 or	 T:A>G:C).	 Here,	 we	 used	 pyrimidines	 to	 denote	 each	
group	such	as	C>A,	C>G,	C>T,	T>A,	T>C,	and	T>G,	and	counted	the	
number	 of	mutations	 detected	 in	 tumor	 samples	 from	WT	 or	 Tg-
SPC-SFN+/−	mice.	They	were	 then	 further	 subdivided	 into	16	pos-
sible	pairs	of	5′	and	3′	nucleotide	neighbors.	The	trinucleotide	bases	
were	verified	using	the	University	of	California	Santa	Cruz	Cancer	
Genomics	Browser	 (https	://genome.ucsc.edu/).	We	compared	mu-
tational	signatures	among	WT,	Tg-SPC-SFN+/−,	and	also	human	can-
cers,	which	we	obtained	from	the	Catalogue	of	Somatic	Mutations	
in	Cancer	 (COSMIC)	database	 (https	://cancer.sanger.ac.uk/cosmic).	
To	compare	mutated	gene	lists	among	4	tumors	that	had	developed	
in	Tg-SPC-SFN+/−	mice,	4-way	Venn	diagrams	were	produced	using	
the	online	Venn	diagram	plotting	tool	(http://bioin	fogp.cnb.csic.es/
tools/	venny/	),	Venny	2.1.0.	To	identify	significantly	mutated	genes	
and	canonical	pathways	induced	by	overexpression	of	hSFN,	we	used	
Ingenuity	 Pathway	 Analysis	 (IPA;	 Qiagen)	 or	 Kyoto	 Encyclopedia	
of	 Genes	 and	Genomes	 (KEGG)	 pathway	 analysis	 through	DAVID	
Bioinformatics	Resources	6.8.	(https	://david.ncifc	rf.gov/)	
2.4 | Expression analysis of mutated genes in human 
lung adenocarcinoma
Mutation	 profiles,	 gene	 expression	 profiles,	 and	 clinical	 data	 for	
482	cases	of	lung	adenocarcinoma	from	The	Cancer	Genome	Atlas	
(TCGA)	 database	 (https	://portal.gdc.cancer.gov/)	were	 used	 to	 ex-
plore	mutation	frequency	and	 its	correlation	with	patient	survival.	
The	percentage	of	lung	adenocarcinoma	patients	having	a	mutation	
F I G U R E  1  Histological	analysis	of	
tumors	that	developed	in	Tg-SPC-SFN+/− 
mice.	A,	Schematic	overview	for	
experimental	design	of	nicotine-derived	
nitrosaminoketone	(NNK)-induced	lung	
tumorigenesis	in	Tg-SPC-SFN+/− and WT 
mice.	At	8	wk	after	birth,	all	mice	were	
given	saline	or	NNK	by	i.p.	injection.	
The	mice	were	observed	for	20	wk	after	
administration	with	NNK	or	saline	and	
killed	at	28	wk	of	age	to	collect	lung	
tumors.	B,	All	tumors	that	developed	
in	Tg-SPC-SFN+/− or WT mice were 
subjected	to	H&E	staining	to	examine	
their	histology.	Tg-SPC-SFN+/−	tumors	
were	more	differentiated	adenoma	
than	WT	tumor,	which	resembles	the	
histology	of	human	lung	adenocarcinoma.	
C,	H&E	and	human	SFN	(hSFN)	
immunohistochemistry	(IHC)	images	of	
representative	paired	samples	of	normal	
lung	and	tumor	tissue	in	Tg-SPC-SFN+/− 
and	WT	mice.	hSFN	was	highly	expressed	
in	tumors,	type	II	alveolar	epithelial	cells,	
and	basal	cells	in	the	bronchial	epithelium	
of	the	normal	lung	in	Tg-SPC-SFN+/− mice
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in	each	gene	was	calculated	as:	number	of	cases	where	each	gene	is	
mutated	/	total	number	of	cases	tested	for	simple	somatic	mutations.	
Survival	plots	for	each	gene	were	examined	using	the	Kaplan-Meier	
method	through	OncoLnc	 (http://www.oncol	nc.org),	a	webtool	for	
investigating	the	association	between	patient	outcome	and	mRNA	
expression	data	for	lung	adenocarcinoma	obtained	from	TCGA.21
2.5 | Statistical analysis
For	 the	 significant	 canonical	 pathways	 associated	 with	 mutated	
genes	 in	 WT	 or	 Tg-SPC-SFN+/−	 tumors,	 we	 used	 the	 Benjamini-
Hochberg	method	and	adjusted	the	Fisher	exact	P	value	threshold	
to	<.05.	Additionally,	we	used	the	log-rank	P	value	for	significance	of	
the	survival	rate	between	low	and	high	gene	expression.
3  | RESULTS
3.1 | Histological examination of tumors attributed 
to NNK treatment in Tg‐SPC‐SFN+/− mice
To	investigate	the	unique	function	of	hSFN	on	tumorigenesis	spe-
cifically	in	the	lung,	we	generated	transgenic	mice	(Tg-SPC-SFN+/− 
mice)	with	overexpression	of	hSFN	rather	than	mouse	SFN	(mSFN).	
As	hSFN	and	mSFN	show	98%	homology	in	amino	acid	sequences	
(Figure	S1A),	we	supposed	that	overexpression	of	hSFN	might	show	
no	toxicity	against	mice,	and	needed	to	distinguish	hSFN	and	mSFN	
to	understand	whether	the	resulting	tumorigenesis	is	due	to	hSFN	
overexpression	or	endogenous	mSFN	expression.11	To	examine	tu-
morigenic	activity	of	hSFN,	we	i.p.	injected	NNK	or	saline	as	a	con-
trol	 into	Tg-SPC-SFN+/−	 and	WT	mice	 (Figure	1A).	 Twenty	weeks	
after	the	treatment,	we	killed	all	mice	and	collected	the	lungs	and	
developing	 tumors,	which	were	 divided	 into	 2	 parts:	 histological	
examinations	and	WES.	First,	we	undertook	H&E	staining	to	exam-
ine	 the	histology	of	 tumors	 that	developed	 in	Tg-SPC-SFN+/− and 
WT	mice.	 Although	 10	 tumors	 developed	 in	 Tg-SPC-SFN+/− mice 
and	 we	 selected	 4	 tumors	 that	 were	 sufficient	 size	 to	 examine	
WES,	 most	 WT	 tumors	 were	 small	 and	 detected	 in	 the	 central	
area	of	the	lung	when	we	undertook	histological	examinations.	We	
obtained	fresh	material	from	only	one	WT	tumor	to	be	applied	to	
WES.	 Interestingly,	tumors	that	developed	in	Tg-SPC-SFN+/− mice 
showed	 papillary	 or	 lepidic	 differentiation,	 which	 are	 major	 his-
tologic	 subtypes	 of	 human	 lung	 adenocarcinoma,	whereas	 those	
in	WT	mice	 showed	 the	 tendency	 to	 have	 poorer	 differentiated	
histology	 (Figure	 1B,C).	Moreover,	 by	 immunohistochemistry,	we	
confirmed	that	tumors	developing	 in	Tg-SPC-SFN+/− mice showed 
positivity	 for	 hSFN	 (Figure	 1C).	 These	 results	 indicated	 that	 the	
transgenic	mice	had	been	generated	successfully	with	appropriate	
gene	recombination.	As	overexpression	of	SFN	is	a	common	event	
facilitating	 tumor	 progression	 in	most	 human	 invasive	 adenocar-
cinomas,5,9	we	 speculated	 that	 genetic	 alterations	 in	 tumors	 that	
developed	in	Tg-SPC-SFN+/−	mice	might	mimic	those	in	human	lung	
adenocarcinoma.
3.2 | Whole‐exome sequencing reveals exonic 
mutational signatures in Tg‐SPC‐SFN+/− tumors
We	 undertook	 WES	 using	 paired	 samples	 of	 normal	 lung	 and	
tumor	 tissue	described	 in	Table	1	 to	 identify	genetic	alterations	
due	to	overexpression	of	hSFN	(Tables	S1	and	S2).	After	exclud-
ing	 single-nucleotide	 polymorphisms,	 the	 mean	 number	 of	 so-
matic	mutations	in	4	samples	of	Tg-SPC-SFN+/−	tumors	was	373.8	
(Figure	S1B).	Among	nonsynonymous	somatic	mutations,	7.3%	of	
them	 in	 average	were	nonsense	mutations	 in	Tg-SPC-SFN+/−	 tu-
mors,	 which	 included	 several	 tumor	 suppressor	 genes,	 such	 as	
Banp, Smarcc1, Epha3, Ccdc154,	and	Ing5	(Figure	S1C).	Therefore,	
we	expect	that	these	tumor	suppressor	genes	harboring	nonsense	
mutations	might	 produce	 incomplete	 forms	 and	 possibly	 induce	
tumor	progression.
Moreover,	 according	 to	 previous	 reports,	 frequent	 somatic	
mutation	 of	 T>C	 or	 T>G	 in	 mice	 is	 caused	 by	 spontaneous	 point	
Sex Treatment Strain Tissue type Genotype
WT-CON Male Saline ICR Normal Wild	type
Tg-CON Male Saline ICR Normal Tg-SPC-SFN+/−
WT Male NNK ICR Normal Tg-SPC-SFN+/−
Adenoma
Tg1 Male NNK ICR Normal Tg-SPC-SFN+/−
Adenoma
Tg2 Male NNK ICR Normal Tg-SPC-SFN+/−
Adenoma
Tg3 Male NNK ICR Normal Tg-SPC-SFN+/−
Adenoma
Tg4 Female NNK ICR Normal Tg-SPC-SFN+/−
Adenoma
Abbreviations:	CON,	control;	NNK,	nicotine-derived	nitrosaminoketone;	Tg,	SFN-transgenic	mouse;	
WT,	wild-type	mouse
TA B L E  1  Details	of	samples	used	for	
whole-exome	sequencing	analysis
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mutations,	unlike	the	situation	in	humans.22	Consistently,	as	shown	
in	Figure	2A,	WT	tumor	showed	a	high	frequency	of	T>C	and	T>G.	
However,	Tg-SPC-SFN+/−	 tumors	 showed	a	high	 frequency	of	C>A	
(Figure	2A),	a	feature	that	is	known	to	be	associated	with	smoking	in	
humans,23	suggesting	that	Tg-SPC-SFN+/−	tumors	might	have	a	close	
resemblance	to	human	tumors.
We	also	examined	 the	mutational	 signatures	of	Tg-SPC-SFN+/− 
and	WT	tumor.	On	the	basis	of	the	COSMIC	database,	the	signatures	
of	Tg-SPC-SFN+/−	tumors	were	similar	to	the	COSMIC	signatures	4	
and	 24,	 which	 show	 a	 high	 frequency	 of	 C>A.24	 Consistent	 with	
our	results,	TCGA	also	indicated	that	signatures	4	and	24	were	fre-
quently	observed	in	human	lung	adenocarcinoma	and	showed	a	high	
frequency	of	C>A	and	C>T	substitutions	(Figure	S2A,B).	The	Tg-SPC-
SFN+/−	tumors	typically	had	a	high	frequency	of	trinucleotide	vari-
ants	such	as	ACA,	ACC,	GCA,	and	GCC	in	C>A	type	and	GCC	in	C>T	
type	(Figure	2B).	However,	GTC	showed	the	highest	percentage	of	
mutations	in	T>G,	both	in	WT	tumor	and	Tg-SPC-SFN+/−	tumors,	in-
dicating	that	GTC	might	be	associated	with	NNK	treatment	or	spon-
taneous	mutations	in	mice	(Figure	2B).
3.3 | Exonic mutational profiles of Tg‐SPC‐
SFN+/− tumors
Next,	we	analyzed	associations	between	the	number	of	mutations	
and SFN	gene	expression	in	lung	adenocarcinoma	patients	in	TCGA	
and	lung	cancer	cell	lines	in	the	COSMIC	database.	The	patients	with	
high	 mutation	 number	 showed	 significantly	 higher	 expression	 of	
SFN	 than	those	with	 low	mutation	number	 (Figure	S3A).	Similar	to	
lung	adenocarcinoma	patients,	 lung	cancer	cell	 lines	with	high	mu-
tation	number,	such	as	HCC827,	A549,	H1975,	Calu-3,	H1755,	and	
H1573,	had	significantly	higher	expression	of	SFN	 than	those	with	
low	mutation	number,	such	as	COR-L105	and	Calu-6	 (Figure	S3B).	
Interestingly,	the	cell	 lines	with	high	number	of	mutations,	such	as	
A549,	H1755,	and	H1573	showed	high	frequency	of	C>A	and	C>T	
substitutions,	 a	 similar	 mutational	 signature	 of	 Tg-SPC-SFN+/−	 tu-
mors	(Figures	2B	and	S3C).
Based	on	these	results,	we	hypothesized	that	Tg-SPC-SFN+/−	tu-
mors	might	be	associated	with	high	mutation	burden,	which	is	a	crit-
ical	 indicator	of	 the	efficacy	of	 immune	 checkpoint	 inhibitors.16,25 
F I G U R E  2  Distribution	of	nucleotide	
alterations	in	Tg-SPC-SFN+/−	tumors	
and	comparison	with	the	human	cancer	
mutational	signature	in	the	COSMIC	
database.	A,	Six	classes	of	somatic	single	
nucleotide	mutations	are	indicated	on	
the	horizontal	axis	and	the	percentages	
of	each	mutation	type	are	displayed	on	
the	vertical	axis.	The	numbers	below	
the	chart	indicate	the	mutation	numbers	
detected	in	each	tumor.	B,	Each	signature	
is	displayed	according	to	the	96-
substitution	classification	defined	by	the	
substitution	class	and	sequence	context	
immediately	5′	and	3′	to	the	mutated	
base.	The	frequency	of	flanking	base	
pairs	in	Tg-SPC-SFN+/−	tumors	is	similar	
to	COSMIC	signatures	4	and	24,	which	
are	closely	associated	with	smoking	and	
aflatoxin	in	human	cancer,	respectively
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Similar	to	the	mutation	burden	in	human	lung	cancer,	which	ranges	
from	0.1	to	100	nonsynonymous	mutations	per	Mb,26	both	Tg-SPC-
SFN+/−	and	WT	tumor	showed	approximately	7.8	per	Mb	(Figure	3A).	
However,	 the	number	of	mutated	genes	was	higher	 in	 all	 Tg-SPC-
SFN+/−	tumors	than	WT	tumor,	indicating	that	the	former	had	muta-
tions	in	various	genes	whereas	WT	tumor	tended	to	have	multipoint	
mutations	in	particular	genes	(Figure	3B).	Additionally,	the	transition	
to	 transversion	 (Ts/Tv)	 ratio	 is	known	to	be	widely	variable	across	
tumor	 types	 depending	 on	 the	 mutagens	 involved	 or	 the	 mech-
anisms	 responsible	 for	DNA	 repair.26	As	 the	mean	Ts/Tv	 ratio	 for	
Tg-SPC-SFN+/−	tumors	was	0.34,	being	similar	to	that	for	human	lung	
adenocarcinoma	(LUAD	Ts/Tv	=	0.44),	Tg-SPC-SFN+/−	tumors	might	
have	characteristics	comparable	to	those	of	human	lung	adenocarci-
noma	(Figures	3C	and	S2C).
Next,	we	analyzed	the	mutation	frequency	in	each	chromosome.	
The	Tg-SPC-SFN+/−	and	WT	tumors	showed	the	highest	frequency	
of	mutated	genes	in	chromosome	7,	including	the	loci	of	Blm, Herc2, 
Nlrp2,	and	Smg1	in	Tg-SPC-SFN+/−	tumors	(Figure	3D	and	Table	S3).
3.4 | Frequently mutated genes in Tg‐SPC‐
SFN+/− tumors
To	 identify	 common	mutated	 genes	 among	 4	 Tg-SPC-SFN+/−	 tu-
mors,	which	were	predicted	to	be	associated	with	tumorigenesis,	
we	drew	Venn	diagrams	using	single-nucleotide	variants	detected	
by	WES	(Figure	4A).	We	detected	73	genes	that	were	commonly	
detected	in	2	or	more	samples	of	Tg-SPC-SFN+/−	tumors	but	not	in	
WT	tumor	(Figure	4B	and	Table	S4).	Consistent	with	the	previous	
study,	which	examined	somatic	mutations	in	NSCLC,18,27	we	found	
that	 Blm, Brd4, Dnmt3b, Herc2, Nlrp2,	 and	 Smg1 were common 
mutated	 genes	 in	 3	 samples	 of	 Tg-SPC-SFN+/−	 tumors,	 whereas	
67	other	genes,	 including	Cdc20, Cdh23, Cul9, Fgf7, Itga6, Kmt2c, 
Mki67, Tbc1d9,	and	Tsc2,	were	present	in	two	samples	of	Tg-SPC-
SFN+/−	 tumors	 (Figure	 4B).	Notably,	 8	 genes	 contained	 identical	
mutation	sites	among	Tg-SPC-SFN+/−	 tumors,	 including	G235E	 in	
Blm,	 I108V	 and	 R124C	 in	 Smg1,	 I92V	 in	Ctbs,	 S283G	 in	Cyb5r2,	
S153A	 in	 Fgf7,	 D665E/H	 in	 Kmt2c,	 H366R	 in	Ovch2,	 and	 L575I	
in Tsc2	 (Table	 S2).	 However,	 according	 to	 TCGA,	 these	mutated	
genes	do	not	have	mutational	hot	spots	in	human	cancers.	Similar	
to	the	previous	study,	in	which	lung	tumors	were	induced	in	mice	
by	exposure	to	carcinogens	such	as	urethane,17	we	detected	Kras 
mutation	(Q61R)	only	in	WT	tumor,	indicating	that	Kras	mutation	
could	work	as	a	driver	mutation	contributing	to	WT	lung	tumori-
genesis	(Table	S2).
Moreover,	 Tg-SPC-SFN+/−	 tumors	 showed	 accumulation	 of	
passenger	 gene	 and	 tumor	 suppressor	 gene	 mutations	 such	 as	
Blm, Dnmt3b, Cyb5r2, Dapk1, Foxp3, Kmt2c,	and	Tsc2	 rather	 than	
a	specific	driver	oncogene	mutation,	such	as	Kras	mutation	in	WT	
tumor	 (Figure	 4B	 and	 Table	 S2).	 From	 these	 results,	 we	 expect	
that	overexpression	of	SFN	would	be	enough	to	induce	tumor	ini-
tiation	and	progression	without	any	driver	mutations,	such	as	Kras 
mutation.
F I G U R E  3  Distinct	mutational	
spectrum	patterns	in	Tg-SPC-SFN+/− 
tumors.	A,	Exonic	mutation	frequencies	
were	calculated	as	the	number	of	
mutations	detected	per	million	bases	
sequenced,	which	were	estimated	from	
the	average	coverage	and	base	coverage	
data	from	whole-exome	sequencing.	
B,	Mutated	genes	were	counted	in	
each	Tg-SPC-SFN+/−	and	WT	tumor.	C,	
Ratios	of	transitions	(Ts;	C>T,	T>C)	and	
transversions	(Tv;	C>A,	C>G,	T>A,	T>G)	
were	calculated	for	Tg-SPC-SFN+/− and 
WT	tumors.	D,	Mutation	frequency	
was	counted	according	to	the	
gene	chromosome	location	in	each	
Tg-SPC-SFN+/−	and	WT	tumor.	Values	
indicate	the	percentage	number	of	
mutated	genes	among	the	total	number	
of	mutated	genes	detected	in	the	each	
chromosome
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3.5 | Impact of mutated genes in mice and human 
lung adenocarcinoma
To	clarify	distinct	signaling	pathways	related	to	tumorigenesis	in	Tg-
SPC-SFN+/−	and	WT	mice,	we	carried	out	pathway	analyses	for	exonic	
mutations	using	the	KEGG	pathway	and	IPA	software.	First,	we	se-
lected	particular	signaling	pathways	related	to	cell	growth	or	cancer,	
such	as	PI3K/AKT	signaling,	ERK/MAPK	signaling,	STAT3	signaling,	
the	DNA	damage	response	and	repair	system,	cell	cycle	signaling,	p53	
signaling,	PTEN	signaling,	and	14-3-3-mediated	signaling,	and	counted	
the	number	of	mutated	genes	categorized	into	those	pathways	in	each	
tumor	using	the	KEGG	pathway	and	IPA	software.	This	revealed	that	
all	Tg-SPC-SFN+/−	tumors	had	a	high	percentage	of	mutated	genes	re-
lated	to	PI3K/AKT	signaling,	such	as	Fgf7, Itga6, Synj2,	and	Tsc2 and 
the	apoptosis	signaling	pathway	(Figure	5A	and	Table	S5).
We	then	collected	all	mutated	genes	in	4	Tg-SPC-SFN+/−	tumors	
and	 investigated	 pathways	 that	 were	 significantly	 enriched	 using	
the	KEGG	pathway	and	IPA	software.	The	KEGG	pathway	analysis	
revealed	 that	 mutated	 genes	 in	 Tg-SPC-SFN+/−	 tumors	 were	 sig-
nificantly	associated	with	pathways	 in	cancer,	ubiquitinated	prote-
olysis,	small-cell	 lung	cancer,	 the	PI3K-AKT	signaling	pathway,	and	
transcriptional	misregulation	 in	 cancer	 (Table	 S6).	 In	 contrast,	 IPA	
software	 analysis	 indicated	 that	 Tg-SPC-SFN+/−	 tumors	 harbored	
gene	 mutations	 that	 were	 significantly	 correlated	 with	 canonical	
pathways	 such	 as	 14-3-3-mediated	 signaling,	 apoptosis	 signaling,	
PTEN	 signaling,	 and	 DNA	 double-strand	 break	 repair	 by	 homolo-
gous	 recombination	 (Table	 S6).	 Taken	 together,	 overexpression	 of	
SFN	in	the	lung	appeared	to	induce	gene	mutations	mainly	involved	
in	PI3K/AKT	signaling	and	apoptosis	signaling	pathways	facilitating	
tumorigenesis.
F I G U R E  4  Frequently	mutated	genes	
identified	in	Tg-SPC-SFN+/−	tumors	
by	whole-exome	sequencing.	A,	Venn	
diagrams	were	used	to	identify	commonly	
mutated	genes	among	4	Tg-SPC-SFN+/− 
tumors.	Numbers	in	each	region	indicate	
the	numbers	of	mutated	genes	detected	
in	Tg-SPC-SFN+/−	tumors.	Percentages	
in	each	region	indicate	the	percentage	
number	of	genes	among	the	total	
number	of	mutated	genes	detected	in	
the	4	Tg-SPC-SFN+/−	tumors.	M,	male;	
F,	female;	Tg,	SFN-transgenic	mouse.	B,	
Somatic	genes	commonly	mutated	among	
Tg-SPC-SFN+/−	tumors	were	selected.	The	
counted	number	indicates	the	mutation	
frequency	of	each	gene	detected	in	
Tg-SPC-SFN+/−	tumors	by	whole-exome	
sequencing.	Each	column	represents	an	
individual	tumor,	and	each	row	denotes	a	
gene.	All	mutations	were	nonsynonymous	
missense	mutations
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Next,	 using	TCGA,	we	 investigated	 the	mutation	 frequency	of	
73	genes	that	were	commonly	mutated	in	Tg-SPC-SFN+/−	tumors	in	
human	lung	adenocarcinomas.	Most	of	the	top-ranked	genes	were	
not	well	known,	and	likely	passenger	mutations	that	do	not	directly	
confer	a	selective	tumor	growth	advantage.	Among	them,	titin	(TTN),	
a	so-called	giant	gene	with	363	coding	exons	in	the	human	genome	
and	 tending	 to	 have	 frequent	mutations	 because	of	 random	DNA	
repair	error,28,29	was	the	top	ranked	gene,	harbored	by	314	of	487	
lung	adenocarcinoma	patients.	Moreover,	HERC2, SMG1,	and	NLRP2,	
which	were	detected	in	3	samples	of	Tg-SPC-SFN+/−	tumors,	also	had	
a	 high	 ranking	 for	mutation	 frequency	 in	 human	 lung	 adenocarci-
noma	(Figure	5B	and	Table	S7).
In	order	to	clarify	the	impact	of	these	gene	alterations	on	prog-
nosis,	overall	survival	was	compared	between	patients	showing	high	
expression	and	those	showing	low	expression	using	TCGA	(Table	S8).	
This	revealed	that	patients	with	high	expression	of	BLM, DNMT3B, 
MKI67, ITGA6,	 or	CDC20	 had	 a	 significantly	 poorer	 outcome	 than	
those	with	low	expression	of	the	genes	(Figure	S4A).	In	contrast,	pa-
tients	with	high	expression	of	NLRP2, CUL9, TBC1D9,	or	CDH23 had 
a	 significantly	more	 favorable	 outcome	 relative	 to	 those	with	 low	
expression	of	these	genes	(Figure	S4B).
In	 summary,	 overexpression	 of	 SFN	 might	 frequently	 induce	 a	
large	number	of	mutations,	most	of	which	are	involved	in	PI3K/AKT	
signaling	 and	 apoptosis	 signaling,	 and	 altered	 expression	 of	 those	
genes	affects	patient	outcome.
4  | DISCUSSION
Recently,	the	genomic	alterations	driving	lung	adenocarcinogenesis	
have	been	investigated	to	clarify	the	molecular	mechanisms	involved,	
discover	novel	drug	targets,	and	screen	candidate	patients	for	clini-
cal	trials	using	next-generation	sequencing.27,30	Extensive	molecular	
analysis	has	shown	that	normal	cells	progressively	acquire	a	variety	
of	genetic	imbalances	that	lead	to	tumorigenesis.31	Tumorigenesis	is	
mediated	by	a	combination	of	events	including	upregulation	of	on-
cogenes	sustaining	proliferative	signaling,	downregulation	of	tumor	
suppressor	genes,	and	also	resistance	to	apoptotic	cell	death,	thus	
enabling	replicative	immortality.32
In	the	present	study,	by	analyzing	tumors	that	developed	in	Tg-
SPC-SFN+/−	mice	after	exposure	to	NNK,	we	showed	that	SFN had po-
tent	oncogenic	functions	causing	distinct	genetic	alterations	during	
the	process	of	tumorigenesis.	As	Tg-SPC-SFN+/−	mice	without	NNK	
treatment	developed	few	but	histologically	similarly	tumors	to	NNK-
induced	 tumors	 in	Tg-SPC-SFN+/−	mice,11	we	consider	 that	overex-
pression	of	hSFN	in	the	lung	in	ICR	mice	robustly	induces	initiation	
F I G U R E  5  Pathway	analysis	for	mutated	genes	in	Tg-SPC-SFN+/−	tumors	and	frequencies	of	commonly	mutated	genes	in	lung	
adenocarcinoma	patients.	A,	IPA	and	KEGG	pathway	analysis	were	used	to	investigate	the	molecular	functions	of	each	of	the	mutated	genes	
in	Tg-SPC-SFN+/−	and	WT	tumors.	The	heatmap	indicates	the	percentages	of	mutated	genes	among	the	total	number	of	mutated	genes	
detected	in	the	each	Tg-SPC-SFN+/−	and	WT	tumor	and	was	drawn	using	Morpheus,	a	webtool	(https	://softw	are.broad	insti	tute.org/morph	
eus/)	.	Commonly	mutated	genes	among	Tg-SPC-SFN+/−	tumors,	which	are	included	in	each	pathway,	are	indicated	in	the	right	column.	B,	
Percentages	of	lung	adenocarcinoma	patients	harboring	each	mutation	commonly	found	in	Tg-SPC-SFN+/−	tumors	are	displayed	in	the	bar	
graph.	TCGA	was	used	for	this	analysis.	Arrows	denote	commonly	mutated	genes	in	3	Tg-SPC-SFN+/−	tumors	apart	from	WT	tumor
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of	 tumor	 formation,	 similar	 to	NNK	exposure.	Moreover,	 all	NNK-
induced	tumors	in	Tg-SPC-SFN+/−	mice	have	high	similarity	to	most	
human	 lung	 adenocarcinomas	 in	 terms	 of	 histology33	 and	 genetic	
profiles,	 including	a	high	frequency	of	passenger	mutations,	a	high	
frequency	of	transversion,	a	large	mutation	burden,	and	smoking-like	
signatures	 (Figures	 1-3,	 S2,	 and	 S3).	Moreover,	 tumors	 that	 devel-
oped	 in	Tg-SPC-SFN+/−	mice	did	not	contain	Kras	mutation,	known	
as	a	driver	mutation	for	murine	lung	cancer.34	Therefore,	we	believe	
that	this	mouse	model	closely	mimics	actual	human	adenocarcinoma.
We	revealed	that	NNK	induced	tumor	formation	accompanied	by	
frequent	C>T	transition	substitution	in	both	Tg-SPC-SFN+/− and WT 
mice	(Figure	2A),	indicating	that	the	high	frequency	of	this	substitu-
tion	is	caused	by	a	defective	DNA	repair	process	attributed	to	NNK.35 
Consistent	with	our	results,	NNK	is	known	to	be	a	strong	tobacco-de-
rived	carcinogen	and	undergoes	metabolism	to	DNA	adducts,	which	
then	bind	to	DNA,	resulting	in	mutation	of	KRAS and STK11,	and	thus	
lung	 tumor	 formation	 in	various	animal	models.36,37	Unlike	 tobacco	
smoke,	which	contains	more	than	70	carcinogenic	compounds	such	as	
benzo[a]pyrene,	which	predominantly	induces	C>A	transversion	mu-
tation,	treatment	of	rats	with	NNK	leads	to	frequent	C>T	transition	
mutation	caused	by	O6-mGua,	which	is	a	highly	promutagenic	adduct	
induced	by	NNK	and	can	be	removed	by	DNA	repair	proteins	such	as	
O-6-methylguanine-DNA	methyltransferase.35,38
In	contrast,	mutated	genes	in	Tg-SPC-SFN+/−	tumors	had	a	high	
frequency	of	C>A	transversion	(Figure	2B).	This	substitution	might	
be	due	to	failure	of	the	transcription-coupled	nucleotide	excision	
repair	machinery,	similar	to	human	mutational	signatures	that	are	
correlated	with	smoking	history.39	Such	mutational	signatures	can	
indicate	 the	cause	of	 somatic	mutations	 such	as	DNA	replication	
infidelity,	 defective	 DNA	 repair	 processes,	 and	 mutagen	 expo-
sure	occurring	throughout	life.40	Among	30	mutational	signatures	
in	 the	COSMIC	 database,	 signature	 4	 is	 the	most	 closely	 related	
to	 lung	 cancers	 associated	 with	 smoking,23,39	 and	 signature	 24	
is	 linked	 to	 liver	 cancer	 and	 exposure	 to	 aflatoxin,	 a	 carcinogen	
produced	 by	 fungi	 in	 nature,39	 both	 of	 which	 show	 similarity	 to	
Tg-SPC-SFN+/−	tumors.
Through	 interaction	 with	 the	 target	 proteins,	 14-3-3	 proteins	
including	SFN	alter	 the	activity,	modifications,	and	 intracellular	 lo-
calization	of	ligands.41-43	In	particular,	SFN	regulates	DNA	repair	fac-
tors	such	as	DNA-PKcs,	when	DNA	is	damaged	by	chemotherapy	or	
radiotherapy	in	human	cancer.44	Based	on	the	previous	report,	we	
assume	 that	 the	high	number	of	gene	mutations	 in	Tg-SPC-SFN+/− 
tumors	might	 be	 due	 to	 binding	with	 unknown	 factor(s),	 which	 is	
associated	with	the	DNA	repair	system.	SFN	might	inhibit	DNA	re-
pair-related	factors,	resulting	in	the	accumulation	of	numerous	gene	
mutations.	 Indeed,	we	 found	 some	mutated	genes	 involved	 in	 the	
DNA	damage	response	and	repair	system	such	as	Blm, Brd4, Herc2, 
Brca1, Pole, Ddb1, Msh6,	 and	 Xrcc1	 only	 in	 Tg-SPC-SFN+/−	 tumors	
(Table	 S5),	 suggesting	 that	 these	 alterations	 could	 also	 indirectly	
accelerate	 dysfunction	 of	 the	 DNA	 repair	 system	 and	 thus	 these	
mutated	genes	might	cause	additional	mutation	again.	High	tumor	
mutation	burden	is	known	to	induce	high	neoantigen	expression,45 
which	enhances	tumor	growth,	invasion,	and	metastasis	by	evasion	
from	immune	attack.46	It	implies	that	Tg-SPC-SFN+/−	might	serve	as	a	
useful	tool	to	evaluate	the	efficacy	of	immune	checkpoint	inhibitors.
Additionally,	our	previous	pull-down	assay	and	LC-MS/MS	analy-
sis	has	identified	SFN	binding	proteins	in	lung	adenocarcinoma	cells	
including	 cell	 cycle-related	proteins	 such	 as	 S-phase	 kinase	 tumor	
progression	(SKP1),10	and	proliferation	related	proteins	such	as	ser-
ine/threonine-protein	kinase	A-Raf	(ARAF)47	and	ubiquitin-specific	
protein	8	 (USP8),	which	particularly	enhances	stability	of	 receptor	
tyrosine	kinase	such	as	epidermal	growth	factor	receptor	and	MET.9 
We	speculate	that,	as	SFN	controls	those	proteins,	tumor	cells	might	
pass	 through	 the	 cell	 cycle	 checkpoint	 even	 though	 they	 recog-
nize	a	 large	number	of	mutations	due	to	insufficient	DNA	repair.48 
Consequently,	SFN	might	induce	a	large	number	of	mutations,	which	
are	predominantly	involved	in	PI3K-AKT	signaling	and	apoptosis	sig-
naling	(Figure	5A),	and	those	mutations	might	boost	canonical	signal-
ing	for	adenocarcinogenesis.
Moreover,	we	revealed	that	Tg-SPC-SFN+/−	tumors	harbored	mu-
tations	of	Blm, Dnmt3b, Mki67, Itga6, Cdc20, Nlrp2, Cul9, Tbc1d9,	and	
Cdh23	 that	were	also	detectable	 in	 lung	adenocarcinoma	patients,	
and	that	the	expression	of	these	genes	was	significantly	correlated	
with	overall	survival	(Figure	S4).	However,	the	mutational	hot	spots	
and	oncogenic	activity	of	these	mutated	genes	in	lung	cancers	have	
not	yet	been	clarified.	Although	there	is	a	possibility	that	these	mu-
tated	genes	might	be	involved	in	lung	adenocarcinogenesis	triggered	
by	 SFN,	 further	 verification	 and	 functional	 analysis	 using	 human	
lung	adenocarcinoma	specimens	will	be	needed	 in	order	to	under-
stand	 the	 overall	 molecular	mechanisms	 involved.	 Additionally,	 as	
WES	has	limitations	to	detect	in	particular	genetic	alterations	such	
as	mutations,	deletions,	and	insertions,	we	are	planning	to	undertake	
whole	genome	amplification-sequencing	or	RNA-sequencing	to	 in-
vestigate	the	amplification	or	expression	of	genes	for	further	study.
Furthermore,	we	examined	the	mutational	landscape	in	both	Tg-
SPC-SFN+/−	tumors	and	WT	tumor.	Compared	to	the	Tg-SPC-SFN+/− 
tumors,	WT	 tumor	 showed	 poorer	 differentiated	 histology,	 higher	
frequency	of	T>C	and	T>G,	and	contained	a	lower	number	of	mutated	
genes.	Additionally,	only	WT	tumor	contained	Kras	mutation.	These	
differences	between	Tg-SPC-SFN+/−	and	WT	tumors	are	very	 inter-
esting.	Unfortunately,	in	the	current	study,	we	could	examine	only	one	
WT	tumor,	as	the	tumorigenic	frequency	is	very	low	in	ICR	mice	by	
NNK	treatment.	Large-scale	examinations	should	be	planned	 in	the	
future	to	make	clear	the	characteristics	of	Tg-SPC-SFN+/−	tumors.
In	summary,	we	characterized	tumors	that	developed	in	Tg-SPC-
SFN+/−	mice	and	found	distinct	exonic	alterations,	remarkably	mim-
icking	the	features	of	human	lung	adenocarcinoma.	We	believe	that	
SFN	overexpression	 is	 critical	 to	human	 lung	adenocarcinogenesis	
and	that	our	mouse	model,	created	by	both	genetic	engineering	and	
carcinogen	 exposure,	would	 be	 a	 valuable	 resource	 for	 preclinical	
examinations	of	therapy	for	lung	adenocarcinoma.
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